0545440 - ÚI 2022 GB eng J - Journal Article
Novák, P. - Schmidt, R. - Kontseková, E. - Kováčech, B. - Smolek, T. - Katina, Stanislav - Fialová, L. - Prčina, M. - Parrak, V. - Dal-Bianco, P. - Brunner, M. - Staffen, W. - Rainer, M. - Ondruš, M. - Ropele, S. - Smíšek, M. - Sivak, R. - Žilka, N. - Winblad, B. - Novák, M.
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
Alzheimers Research & Therapy. Roč. 10 (2018), č. článku 108. E-ISSN 1758-9193
Keywords : truncated tau * mouse model * dementia * antibody * immunogenicity * accurate * trials * safety * robust * an1792 * Tau * Alzheimer's disease * Vaccine * Immunotherapy * Active immunotherapy * Clinical trial * Neurofibrillary pathology
Impact factor: 6.142, year: 2018
Permanent Link: http://hdl.handle.net/11104/0322126
Novák, P. - Schmidt, R. - Kontseková, E. - Kováčech, B. - Smolek, T. - Katina, Stanislav - Fialová, L. - Prčina, M. - Parrak, V. - Dal-Bianco, P. - Brunner, M. - Staffen, W. - Rainer, M. - Ondruš, M. - Ropele, S. - Smíšek, M. - Sivak, R. - Žilka, N. - Winblad, B. - Novák, M.
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
Alzheimers Research & Therapy. Roč. 10 (2018), č. článku 108. E-ISSN 1758-9193
Keywords : truncated tau * mouse model * dementia * antibody * immunogenicity * accurate * trials * safety * robust * an1792 * Tau * Alzheimer's disease * Vaccine * Immunotherapy * Active immunotherapy * Clinical trial * Neurofibrillary pathology
Impact factor: 6.142, year: 2018
Permanent Link: http://hdl.handle.net/11104/0322126